Schizophrenia and substance abuse comorbidity: Nicotine addiction and the neonatal quinpirole model

Developmental Neuroscience

Volumn 34, Issue 2-3, 2012, Pages 140-151

  Brown, Russell W ^a   Maple, Amanda M ^a   Perna, Marla K ^a   Sheppard, A Brianna ^a   Cope, Zackary A ^a   Kostrzewa, Richard M ^b  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b East Tennessee State University   (United States)

Author keywords

Animal model; Dopamine; Drugs of abuse; Neonatal quinpirole model; Psychiatric disorders

Indexed keywords

AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE GROWTH FACTOR; NEUROTROPHIN; NICOTINE; QUINPIROLE;

ANHEDONIA; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DISEASE MODEL; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; NEGATIVE SYNDROME; NERVE ENDING; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR SENSITIVITY; SCHIZOPHRENIA; SELF MEDICATION; SMOKING CESSATION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE;

ANIMALS; BEHAVIOR, ADDICTIVE; DISEASE MODELS, ANIMAL; NICOTINE; QUINPIROLE; SCHIZOPHRENIA; TOBACCO USE DISORDER;

EID: 84866277053     PISSN: 03785866     EISSN: 14219859     Source Type: Journal    
DOI: 10.1159/000338830     Document Type: Article

References (111)

1. Chambers RA: A nicotine challenge to the self-medication hypothesis in a neurodevelopmental animal model of schizophrenia. J Dual Diagn 2009; 5: 139-148.
2. Tollefson GD: Update on new atypical antipsychotics. J Clin Psychiatry 1996; 57: 318- 319.
3. Pinkham AE, Gur RE, Gur RC: Affect recognition deficits in schizophrenia: Neural substrates and psychopharmacological implications. Expert Rev Neurother 2007; 7: 807-816.
4. Heresco-Levy U: Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg Drugs 2005; 10: 827-824.
5. Lacroix L, Broersen LM, Feldon J, Weiner I: Effects of local infusions of dopaminergic drugs into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine induced activity. Behav Brain Res 2000; 107: 111-118.
6. Timofeeva OA, Levin ED: Idazoxan blocks the nicotine-induced reversal of the memory impairment caused by the NMDA glutamate receptor antagonist dizocilpine. Pharmacol Biochem Behav 2008; 90: 372-381.
7. Marsden CA, King MV, Fone KC: Influence of social isolation in the rat on serotonergic function and memory - relevance to models of schizophrenia and the role of 5-HT6 receptors. Neuropharmacology 2011; 61: 400- 407.
8. Lipska BK, Weinberger DR: A neurodevelopmental model of schizophrenia: Neonatal disconnection of the hippocampus. Neurotox Res 2002; 4: 469-475.
9. Sams-Dodd F, Lipska BK, Weinberger DR: Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 1997; 132: 303-310.
10. Harrison PJ: The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999; 122: 593- 624.
11. Harrison PJ, Eastwood SL: Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 2000; 11: 508-519.
12. Harrison PJ: The hippocampus in schizophrenia: A review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology 2004; 174: 151- 162.
13. Andia AM, Zisook S, Heaton RK, Hesselink J, Jernigan T, Kuck J, Morganville J, Braff DL: Gender differences in schizophrenia. J Nerv Ment Dis 1995; 183: 22-28.
14. Lohr JB, Flynn K: Smoking and schizophrenia. Schizophr Res 1992; 8: 93-102.
15. Lyon ER: A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv 1999; 50: 1346-1350.
16. Jeste DV, Lindamer LA, Evans J, Lacro JP: Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 1996; 32: 243- 251.
17. Hymowitz N, Jaffe FE, Gupta A, Feuerman M: Cigarette smoking among patients with mental retardation and mental illness. Psychiatr Serv 1997; 48: 100-102.
18. McCreadie RG, Kelly C: Patients with schizophrenia who smoke. Private disaster, public resource. Br J Psychiatry 2000; 176: 109-112.
19. Mortensen PB, Juel K: Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183-189.
20. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan-Sarin S, Jatlow PI, Wexler BE, George TP: Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: Involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005; 62: 649-659.
21. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I: The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438- 452.
22. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J: Role of the smoking- induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119-127.
23. Glassman AH: Cigarette smoking: Implications for psychiatric illness. Am J Psychiatry 1993; 150: 546-553.
24. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM: Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986; 90: 468-470.
25. Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL: The selective dopamine D 3 receptor antagonist SB- 277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006; 9: 585-602.
26. Perry PJ, Miller DD, Arndt SV, Smith DA, Holman TL: Haloperidol dosing requirements: The contribution of smoking and nonlinear pharmacokinetics. J Clin Psychopharmacol 1993; 13: 46-51.
27. Vinarova E, Vinar O, Kalvach Z: Smokers need higher doses of neuroleptic drugs. Biol Psychiatry 1984; 19: 1265-1268.
28. Diaz FJ, de Leon J, Josiassen RC, Cooper TB, Simpson GM: Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 2005; 72: 131-135.
29. Winterer G: Why do patients with schizophrenia smoke? Curr Opin Psychiatry 2010; 23: 112-119.
30. Yassa R, Lal S, Korpassy A, Ally J: Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987; 22: 67-72.
31. Pan L, Vander Stichele R, Rosseel MT, Berlo JA, De Schepper N, Belpaire FM: Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit 1999; 21: 489-496.
32. Addington J, el-Guebaly N, Campbell W, Hodgins DC, Addington D: Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998; 155: 974-976.
33. Breckenridge JS: Smoking by outpatients. Hosp Community Psychiatry 1990; 41: 454- 455.
34. Ziedonis DM, George TP: Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997; 23: 247-254.
35. Freedman R: Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 164: 1269.
36. Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE: Varenicline as a smoking cessation aid in schizophrenia: Effects on smoking behavior and reward sensitivity. Psychopharmacology 2012; 219: 25-34.
37. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S, Sershen H, Lajtha A: Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009; 110: 149-155.
38. Liu ME, Tsai SJ, Jeang SY, Peng SL, Wu SL, Chen MC, Tsai YL, Yang ST: Varenicline prevents affective and cognitive exacerbation during smoking abstinence in male patients with schizophrenia. Psychiatry Res 2011; 190: 79-84.
39. Berg SA, Chambers RA: Accentuated behavioral sensitization to nicotine in the neonatal ventral hippocampal lesion model of schizophrenia. Neuropharmacology 2008; 54: 1201-1207.
40. Rodvelt KR, Kracke GR, Schachtman TR, Miller DK: Ketamine induces hyperactivity in rats and hypersensitivity to nicotine in rat striatal slices. Pharmacol Biochem Behav 2008; 91: 71-76.
41. Stevens KE, Johnson RG, Rose GM: Rats reared in social isolation show schizophrenia- like changes in auditory gating. Pharmacol Biochem Behav 1997; 58: 1031-1036.
42. Radek RJ, Miner HM, Bratcher NA, Decker MW, Gopalakrishnan M, Bitner RS: Alpha- 4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacology 2006; 187: 47-55.
43. Rezvani AH, Tizabi Y, Getachew B, Hauser SR, Caldwell DP, Hunter C, Levin ED: Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: Interactions with clozapine actions and attentional performance in rats. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1030-1040.
44. Chambers RA, Moore J, McEvoy JP, Levin ED: Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 1996;5:587-594.
45. van Nimwegen L, de Haan L, van Beveren N, van den Brink W, Linszen D: Adolescence, schizophrenia and drug abuse: A window of vulnerability. Acta Psychiatr Scand Suppl 2005; 427: 35-42.
46. Mäki P, Veijola J, Jones PB, Murray GK, Koponen H, Tienari P, Miettunen J, Tanskanen P, Wahlberg KE, Koskinen J, Lauronen E, Isohanni M: Predictors of schizophrenia - a review. Br Med Bull 2005; 73-74: 1-15.
47. Weiser M, Reichenberg A, Grotto I, Yasvitzky R, Rabinowitz J, Lubin G, Nahon D, Knobler HY, Davidson M: Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: A historical-prospective cohort study. Am J Psychiatry 2004; 161: 1219-1223.
48. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Constable PM, Jansons S, Wilhelm K, Moeller-Saxone K: Characteristics of smokers with a psychotic disorder and implications for smoking interventions. Psychiatry Res 2007; 150: 141-152.
49. Deas D, Brown ES: Adolescent substance abuse and psychiatric comorbidities. J. Clin Psychiatry 2006; 67:e02.
50. Martin LF, Kem WR, Freedman R: Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004; 174: 54-64.
51. Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rodefer JS: Selective nicotinic acetylcholine receptor agonists: Potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr Opin Investig Drugs 2008; 9: 47-56.
52. Mueser KT, Noordsy DL, Drake RE, Fox L: Integrated Treatment for Dual Disorders: A Guide to Effective Practice. New York, Guildford Press, 2003.
53. Kostrzewa RM, Hamdi A, Kostrzewa FP: Production of prolonged supersensitization of dopamine D 2 receptors. Eur J Pharmacol 1990; 183: 42-49.
54. Kostrzewa RM: Dopamine receptor supersensitivity. Neurosci Biobehav Rev 1995; 19: 1-21.
55. Kostrzewa RM, Brus R: Ontogenetic homologous supersensitization of quinpirole-induced yawning in rats. Pharmacol Biochem Behav 1991; 39: 39-50.
56. Kostrzewa RM, Brus R, Rykaczewska M, Plech A: Low-dose quinpirole ontogenetically sensitizes to quinpirole-induced yawning in rats. Pharmacol Biochem Behav 1993; 44: 487-489.
57. Kostrzewa RM, Guo J, Kostrzewa FP: Ontogenetic quinpirole treatement induces vertical jumping activity in rats. Eur J Pharmacol 1993; 239: 41-58.
58. Seeman P: All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 2011; 17: 118-132.
59. Crow TJ: Schizophrenia: The nature of the psychological disturbance and its possible neurochemcial basis. Ciba Found Symp 1979; 69: 335-343.
60. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991; 148: 1474-1486.
61. Kokkinidis L, Anisman H: Amphetamine models of paranoid schizophrenia: An overview and elaboration of animal experimentation. Psychol Bull 1980; 88: 551-579.
62. Cotter D, Pariante CM: Stress and the progression of the developmental hypothesis of schizophrenia. Br J Psychiatry 2002; 181: 363-365.
63. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B: Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918-925.
64. Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R: Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002; 59: 1085-1096.
65. Brown RW, Gass JT, Kostrzewa RM: Ontogenetic quinpirole treatment produce spatial memory deficits and enhance skilled reaching in adult rats. Pharm Biochem Behav 2002; 72: 591-600.
66. Brown RW, Perna MK, Schaefer TL, Williams MT: The effects of adulthood nicotine treatment on D 2 -mediated behavior and neurotrophins of rats neonatally treated with quinpirole. Synapse 2006; 59: 253-259.
67. Brown RW, Perna MK, Maple AM, Wilson TD, Miller BE: Adulthood olanzapine treatment fails to alleviate decreases of ChAT and BDNF RNA expression in rats quinpiroleprimed as neonates. Brain Res 2008; 1200: 66-77.
68. Brown, RW, Thompson KD, Thompson KN, Thacker SK, Ward JJ, Kostrzewa RM: Adulthood nicotine treatment alleviates behavioural impairments in rats neonatally treated with quinpirole: Possible roles of acetylcholine function and neurotrophic factor expression. Eur J Neurosci 2004; 19: 1634-1642.
69. Brown RW, Thompson KD, Thompson KN, Ward JJ, Thacker SK, Williams MT, Kostrzewa RM: Adulthood nicotine treatment alleviates behavioural impairments in rats neonatally treated with quinpirole: Possible roles of acetylcholine function and neurotrophic factor expression. Eur J Neurosci 2004; 19: 1634-1642.
70. Brown RW, Thompson KN, Click IA, Best RA, Thacker SK, Perna MK: The effects of eticlopride on Morris water task performance in male and female rats neonatally treated with quinpirole. Psychopharmacology 2005; 180: 234-240.
71. Brown RW, Perna MK, Noel DM, Whittemore JD, Lehmann J, Smith ML: Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole. Behav Pharmacol 2011; 22: 374-378.
72. Chen WJ, Andersen KH, West JR: Cocaine exposure during the brain growth spurt: Studies of neonatal survival, somatic growth, and brain development. Neurotoxicol Teratol 1993; 15: 267-273.
73. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH: Dopamine agonist-induced yawning in rats: A dopamine D 3 receptor-mediated behavior. J Pharmacol Exp Ther 2005; 314: 310-319.
74. Cooper SJ, Rusk IN, Barber DJ: Yawning induced by the selective dopamine D 2 agonist N-0437 is blocked by the selective dopamine autoreceptor antagonist (+)-UH 232. Physiol Behav 1989; 45: 1263-1266.
75. Maple AM, Perna MK, Parlaman JP, Stanwood GD, Brown RW: Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex. Eur J Neurosci 2007; 26: 2532-2538.
76. Neubig RR: Regulators of G protein signaling (RGS proteins): Novel central nervous system drug targets. J Pept Res 2002; 60: 312- 316.
77. Neubig, RR Siderovski DP: Regulators of Gprotein signalling as new central nervous system drug targets. Nat Rev Drug Discov 2002; 1: 187-189.
78. Xu X, Zeng W, Popov S, Berman DM, Davignon I, Yu K, Yowe D, Offermanns S, Muallem S, Wilkie TM: RGS proteins determine signaling specificity of Gq-coupled receptors. J Biol Chem 1999; 274: 3549-3556.
79. Hollinger S, Hepler JR: Cellular regulation of RGS proteins: Modulators and integrators of G protein signalling. Pharmacol Rev 2002; 54: 527-555.
80. Seeman P, Ko F, Jack E, Greenstein R, Dean B: Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 2007; 61: 303-309.
81. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T: Psychosis pathways converge via D2high dopamine receptors. Synapse 2006; 60: 319-346.
82. Thacker SK, Perna MK, Ward JJ, Schaefer TL, Williams MT, Kostrzewa RM, Brown RW: The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole. Eur J Neurosci 2006; 24: 2075-2083.
83. Cuesta MJ, Jalón EG, Campos MS, Peralta V: Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009; 194: 439-445.
84. Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, Katsafouros K, Lykouras L: Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2010; 11: 251-255.
85. Perna MK, Cope ZA, Maple AM, Longacre ID, Correll JA, Brown RW: Nicotine sensitization in adult male and female rats quinpirole- primed as neonates. Psychopharmacology 2008; 99: 67-75.
86. Sheppard B, Lehmann J, Cope ZA, Brown RW: Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: Role of D 2 and D 3 receptor subtypes. Behav Neurosci 2009; 123: 1296-1308.
87. Bevins RA, Palmatier MI: Nicotine-conditioned locomotor sensitization in rats: Assessment of the US-preexposure effect. Behav Brain Res 2003; 143: 65-74.
88. Coolon RA, Cain ME: Effects of mecamylamine on nicotine-induced conditioned hyperactivity and sensitization in differentially reared rats. Pharmacol Biochem Behav 2009; 93: 59-66.
89. Palmatier MI, Bevins RA: Examination of GABAergic and dopaminergic compounds in the acquisition of nicotine-conditioned hyperactivity in rats. Neuropsychobiology 2002; 45: 87-94.
90. Perna MK, Henderson YO, Bruner CL, Brown RW: An analysis of nicotine conditioned place conditioning in early postweanling and adolescent rats neonatally treated with quinpirole. Behav Brain Res 2011; 220: 254-261.
91. Tizabi Y, Copeland RL Jr, Brus R, Kostrzewa RM: Nicotine blocks quinpirole-induced behavior in rats: Psychiatric implications. Psychopharmacology 1999; 145: 433-441.
92. Freedman R, Hall M, Adler LE, Leonard S: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38: 22-33.
93. Freedman R, Adler LE, Myles-Worsley M, Nagamoto HT, Miller C, Kisley M, McRae K, Cawthra E, Waldo M: Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model. Arch Gen Psychiatry 1996; 53: 1114-1121.
94. Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG, Perry RH, Perry EK: Nicotine binding in human striatum: Elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 2000; 98: 79-87.
95. Durany N, Zöchling R, Boissl KW, Paulus W, Ransmayr G, Tatschner T, Danielczyk W, Jellinger K, Deckert J, Riederer P: Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000; 287: 109-112.
96. Smith RF: Animal models of periadolescent substance abuse. Neurotoxicol Teratol 2003; 25: 291-293.
97. Spear LP: The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000; 24: 417-463.
98. Andersen SL, Teicher MH: Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 2000; 24: 137-141.
99. Nowak P, Brus R, Kostrzewa RM: Amphetamine- induced enhancement of neostriatal in vivo microdialysate dopamine content in rats, quinpirole-primed as neonates. Pol J Pharmacol 2001; 53: 319-329.
100. Cope ZA, Huggins KN, Sheppard AB, Noel DM, Roane DS, Brown RW: Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood. Synapse 2010; 64: 289-300.
101. Wolf ME, White FJ, Nassar R, Brooderson RJ, Khansa MR: Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J Pharmacol Exp Ther 1993; 264: 249-255.
102. Kaiser S, Wonnacott S: Alpha-bungarotoxin- sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol Pharmacol 2000; 58: 312-318.
103. Northrop NA, Smith LP, Yamamoto BK, Eyerman DJ: Regulation of glutamate release by 7 nicotinic receptors: Differential role in methamphetamine-induced damage to dopaminergic and serotonergic terminals. J Pharmacol Exp Ther 2011; 336: 900-907.
104. McClernon FJ: Neuroimaging of nicotine dependence: key findings and application to the study of smoking-mental illness comorbidity. J Dual Diagn 2009; 5: 168-178.
105. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB: Single photon emission computerized tomography imaging of amphetamine- induced dopamine release in drugfree schizophrenic subjects. Proc Natl Acad Sci USA 1996; 93: 9235-9240.
106. Gilbert DG, Gilbert BO: Personality, psychopathology, and nicotine response as mediators of the genetics of smoking. Behav Genet 1995; 25: 133-147.
107. Perez-Polo JR, Westlund K, Hall, K, Livingston K: Levels of serum nerve growth factor in schizophrenia. Birth Defects Orig Artic Ser 1978;14:311-321.
108. Durany N, Michel T, Zöchling R, Boissl KW, Cruz-Sánchez FF, Riederer P, Thome J: Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001;52:79-86.
109. Jindal RD, Pillai AK, Mahadik SP, Eklund K, Montrose DM, Keshavan MS: Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia. Schizophr Res 2010;119:47-51.
110. Bird ED, Spokes EG, Barnes J, MacKay AV, Iversen LL, Shepherd M: Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 1977;2:1157-1158.
111. Geyer MA, Krebs-Thomson K, Braff DL,Swerdlow NR: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology Berl 2001;156: 117-154.